Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion

NCT05037968 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2024-06-10
Last updated
2026-10-19

Condition(s) studied

Degenerative Disc DiseaseSpine FusionLeg Pain and/or Back Pain

Investigational drug(s) / intervention(s)

MagnetOs Flex MatrixTrinity Elite

MagnetOs Flex Matrix: Procedure: Instrumented Posterolateral Lumbar Fusion

Trinity Elite: Procedure: Instrumented Posterolateral Lumbar Fusion

Study summary

This is a phase IV post-marketing study for MagnetOs Flex Matrix. MagnetOs Flex Matrix is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease and undergoing spinal fusion surgery.

In this study, MagnetOs Flex Matrix will be used according to the latest U.S. Instructions For Use, specifically as a bone graft extender mixed with autograft in a 1:1 vol.% in the posterolateral spine.

Trinity Elite will also be used according to its latest IFU approved in the US. Specifically, this cellular based allograft is an allograft intended for the treatment of musculoskeletal defects.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient is able to read/be read, understand, and provide written informed consent and has signed the Investigational Review Board (IRB) approved informed consent. * Male or female patient ≥ 18 years old. * Patients with leg pain, and/or back pain requiring up to four-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1) * Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment. Exclusion Criteria: * Requires \> four-level fusion or expected to need secondary intervention within one year following surgery. * Had prior PLF fusion or attempted PLF fusion at the involved levels * Had previous decompression at the involved levels. * Women who are or intend to become pregnant within the next 12 months * To treat conditions in which general bone grafting is not advisable. * In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g., defect site stabilization is not possible). * In case of significant vascular impairment proximal to the graft site. * In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta or Paget's Disease) that affect bone or wound healing. * In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis). * When intraoperative soft tissue coverage is not planned or possible. * Receiving treatment with medication interfering with calcium metabolism. * Had leg pain, and/or back pain related to a benign or malignant tumor. * Had history or presence of active malignancy. * Has known substance abuse, psychiatric disorder, or condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements. * Is involved in active litigation relating to his/her spinal condition. * Has participated in an investigational study within 30 days prior to surgery for study devices.

Primary outcome measure(s)

  • Radiographic Fusion by CT Scan — Month 12
    The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.

Trial sites (9)

FacilityCityRegionStatus
Hartford Hospital Hartford Connecticut Recruiting
Central CT Neurosurgery & Spine New Britain Connecticut Recruiting
Rush University Medical Center Chicago Illinois Recruiting
MedStar Health Research Institute Columbia Maryland Recruiting
Michigan Orthopedic Surgeons Bloomfield Hills Michigan Recruiting
Pinehurst Surgical Clinic Pinehurst North Carolina Recruiting
The Ohio State University Columbus Ohio Recruiting
Huntsman Spinal Clinic Salt Lake City Utah Recruiting
Inova Healthcare Fairfax Virginia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05037968 on ClinicalTrials.gov ↗ ← All trials in the USA